Home
Campaigns
Grand Challenges Virtual Roundtable Series

Grand Challenges Virtual Roundtable Series

IU Grand Challenges: Progress and Impact

Grand Challenges are major large-scale problems facing humanity that can be solved only by teams of dedicated researchers working across disciplines in collaboration with community partners. IU has three Grand Challenges initiatives in progress: Precision Health, Prepared for Environmental Change, and Responding to the Addictions Crisis.

The Office of the Vice President for Research is pleased to host a series of virtual roundtables to share progress and stories of impact from the innovative research empowered by IU's Grand Challenges program. Roundtable discussions will feature Grand Challenge researchers and partners, and offer participants the chance to engage via live Q&A.

Looking for previous roundtable recordings? Find them in the archive.

Register today

Precision Health Initiative: Multiple Myeloma Roundtable

Precision Health Initiative: Multiple Myeloma Roundtable, Oct. 25, 3 p.m.

Rafat Abonour, M.D., Harry and Edith Gladstein Professor of Cancer Research

Abonour joined the IU School of Medicine in 1995, where he is also professor of medicine, professor of pathology & laboratory medicine, and director of Multiple Myeloma, Waldenstrom's Disease and Amyloidosis Program. As leader of the multiple myeloma program, he has practiced research using IMID's and proteasome inhibitors. With the help of the IU Grand Challenges program, Abonour and his team have created infrastructure to support research aimed at preventing myeloma and improving the treatment of those suffering from the disease, especially those with high-risk disease where both remission and survival are short. He is also active with the international Myeloma Foundation and the American Society of Hematology (ASH). His work with ASH is focused on developing a larger set of patient data to help understand the natural course of myeloma. Abonour's work has been published in Nature Medicine and New England Journal of Medicine, among others.

Dorothy Frapwell, multiple myeloma patient

Frapwell joined the IU legal staff in 1975 as an associate university counsel. For a dozen years, beginning in 1978, she served as the IU Medical Center attorney, advising doctors and administrators on matters of patient care, ethics, hospital law and medical education. In 1990, she was named special counsel to the president and associate university counsel. In 1994, she was named university counsel, heading an office that includes six associate attorneys in Bloomington, Ind., and Indianapolis. She was appointed vice president and general counsel in 2006. Throughout the course of her career, Frapwell advised the trustees of IU, four university presidents and other senior IU administrators. She retired from IU in 2012. Frapwell holds a B.S. degree from Penn State University and a J.D. from the IU Maurer School of Law. She served on the Maurer School's board of visitors for 16 years and as a member of the law alumni board, culminating in a term as president in 1993. She was inducted into the Maurer School of Law's Academy of Law Alumni Fellows and has received the IU President Medal for Excellence.

Responding to the Addictions Crisis Roundtable, Sept. 30, 10 a.m.

Joshua W. Brown, professor of psychological and brain sciences, IU Bloomington

Brown holds joint appointments in neuroscience and cognitive science at IU Bloomington, where he directs the Cognitive Control laboratory. He holds a B.S. in mechanical engineering from UC San Diego and a Ph.D. in cognitive and neural systems from Boston University, where he developed computational neural models of higher cognitive function. Brown has postdoctoral experience with awake-behaving monkey single-unit neurophysiology and extensive experience with human functional MRI and computational neural models of systems neuroscience and cognition, especially of goal-directed behavior. He has published numerous papers on the cognitive neuroscience of addiction, including how risk and reward are represented in the brain, how neural activity signals the risk of addiction and the effects of recovery from addiction. Brown developed the world’s first lab to study decisions to vape while subjects vape nicotine in the fMRI scanner. With IU Grand Challenges funding, he is developing a new non-invasive deep neurostimulation procedure aimed at treating addiction with low-cost electrical neurostimulation of the brain areas central to addiction.

Andrea Hohmann, Linda and Jack Gill Chair and professor of psychological and brain sciences, IU Bloomington

Hohmann's research goal is to identify novel therapeutic interventions for treating pain that lack abuse liability and adverse side effects. She has identified enzymes implicated in endocannabinoid deactivation as novel therapeutic targets for pain and stress-related disorders. Hohmann’s lab has focused on harnessing the therapeutic potential of the endocannabinoid signaling system to suppress neuropathic pain while minimizing unwanted side effects (i.e., psychoactivity and addiction) and has identified functional roles of the endocannabinoid system in the nervous system and mapped its distribution in sensory pathways. The lab also has disrupted protein-protein interactions downstream of NM.D.A receptors to suppress pronociceptive signaling cascades without the adverse effects of NM.D.AR antagonists (i.e., by targeting interactions between neuronal nitric oxide synthase and its upstream [PSD95] or downstream [NOS1AP] protein partners). The laboratory combines approaches from behavioral pharmacology, neurophysiology, neuroanatomy, biochemistry, and molecular biology. Hohmann earned her BSc, ScM, and Ph.D. from Brown University.

Alex Straiker, senior research scientist, Gill Center and Department of Psychological and Brain Sciences, IU Bloomington

Straiker holds a Ph.D. from UC San Diego. The focus of his work is the neuropharmacology and physiology of drugs of abuse, particularly cannabinoids, and more recently, opiates. Cannabinoids and opiates are important drugs of abuse and have a role in human history dating back thousands of years. Only recently have we begun to learn the intimate details of how these drugs actually work in the body. By all accounts, cannabinoids and opiates are part of a complex web of receptors, transporters, enzymes and signaling molecules, each subject to modulation. The precise workings of endocannabinoid and opiate signaling, and even the identity of the endogenous ligand at a given synapse, generally remain an open question. Straiker’s primary approach is to use neurophysiology in combination with molecular biology and anatomy to investigate specific mechanisms of signaling and their roles in health and disease. Much of his recent work has focused on cannabinoid function in the eye, including drug-development projects relating to glaucoma. Recently, he has initiated a drug development project in collaboration with IU chemist Michael Van Nieuwenhze to develop an alternative to the opiate antidote naloxone.

Grand Challenges Virtual Roundtable Series

IU Grand Challenges: Progress and Impact

Register today

Precision Health Initiative: Multiple Myeloma Roundtable, Oct. 25, 3 p.m.

Rafat Abonour, M.D., Harry and Edith Gladstein Professor of Cancer Research

Dorothy Frapwell, multiple myeloma patient

Responding to the Addictions Crisis Roundtable, Sept. 30, 10 a.m.

Joshua W. Brown, professor of psychological and brain sciences, IU Bloomington

Andrea Hohmann, Linda and Jack Gill Chair and professor of psychological and brain sciences, IU Bloomington

Alex Straiker, senior research scientist, Gill Center and Department of Psychological and Brain Sciences, IU Bloomington

FIND

TOOLS

FORMS & POLICIES

DATA & REPORTS

AWARD RESOURCES